Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Australia-based CSL Limited, a specialty biopharmaceutical company, held discussions with the US Federal Trade Commission (FTC) regarding its proposed acquisition of Talecris Biotherapeutics. Talecris is a US-based biotherapeutic and biotechnology company engaged in the development of critical care treatments.
Subscribe to our email newsletter
Dr. McNamee, MD of CSL, has presented the pro-competitive arguments of CSL’s case with the FTC staff, including efficiencies and benefits to consumers resulting out of the acquisition, put forward the potential remedies that may enable approval and discussed the consideration of the case.
Following the review of CSL’s case and remedy proposals, FTC staff has recommended that the Commissioners initiate legal action in the US District Court to stop the transaction. A vote and decision by the Commissioners is pending, expected to be announced by 28 May 2009.